Armata Pharmaceuticals, Inc.
ARMPAMEXHealthcare● Active
$7.57
+$0.07(+0.93%)
Market Cap$277900756
P/E Ratio—
52W High$16.34
52W Low$1.74
Armata Pharmaceuticals, Inc. (ARMP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARMP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.39
Est. -$0.38 · -2.6%
Revenue
$0.00B
Est. $0.00B · +6.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ARMP reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.48 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.38 | -$0.39 | -2.6% | $0.00B | $0.00B | +6.6% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -$0.19 | -$0.51 | -168.4% | $0.00B | $0.00B | +48.6% |
| — Q4 FY2025 | Nov 12, 2025 | -$0.42 | -$0.42 | +0.0% | $0.00B | $0.00B | +56.6% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.39 | -$0.32 | +17.9% | $0.00B | $0.00B | +57.2% |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.38 | -$0.20 | +47.4% | $0.00B | $0.00B | -64.4% |
| ▲ Q1 FY2025 | Mar 20, 2025 | -$0.35 | -$0.23 | +34.3% | $0.00B | $0.00B | -20.8% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.28 | -$0.15 | +46.4% | $0.00B | $0.00B | +90.6% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.48
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.39
EPS Est.
-$0.38
EPS Surpr.
-2.6%
Revenue
$0.00B
Q1 FY2026
Mar 25, 2026Miss
EPS Actual
-$0.51
EPS Est.
-$0.19
EPS Surpr.
-168.4%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025
EPS Actual
-$0.42
EPS Est.
-$0.42
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.39
EPS Surpr.
+17.9%
Revenue
$0.00B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.38
EPS Surpr.
+47.4%
Revenue
$0.00B
Q1 FY2025
Mar 20, 2025Beat
EPS Actual
-$0.23
EPS Est.
-$0.35
EPS Surpr.
+34.3%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.15
EPS Est.
-$0.28
EPS Surpr.
+46.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q3 FY2026 | $-0.39 | $-0.39 | $-0.39 | 1 |
| Q2 FY2026 | $-0.45 | $-0.45 | $-0.45 | 1 |
| Q1 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q4 FY2025 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2025 | $-0.42 | $-0.42 | $-0.42 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -2.6% | $9.00 | $8.82 | -2.00% |
| ▼ Q1 FY2026 | Mar 25, 2026 | -168.4% | $8.21 | $8.61 | +4.87% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +0.0% | $6.75 | $6.69 | -0.89% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +17.9% | $2.36 | $2.46 | +4.24% |
| ▲ Q2 FY2025 | May 14, 2025 | +47.4% | $1.42 | $1.38 | -2.82% |
| ▲ Q1 FY2025 | Mar 20, 2025 | +34.3% | $1.99 | $2.01 | +1.01% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +46.4% | $2.75 | $2.72 | -1.09% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -25.0% | $2.55 | $2.71 | +6.27% |
Q2 FY2026-2.00%
Report Date
May 13, 2026
EPS Beat/Miss
-2.6%
Price Before
$9.00
Price After
$8.82
Q1 FY2026+4.87%
Report Date
Mar 25, 2026
EPS Beat/Miss
-168.4%
Price Before
$8.21
Price After
$8.61
Q4 FY2025-0.89%
Report Date
Nov 12, 2025
EPS Beat/Miss
+0.0%
Price Before
$6.75
Price After
$6.69
Q3 FY2025+4.24%
Report Date
Aug 12, 2025
EPS Beat/Miss
+17.9%
Price Before
$2.36
Price After
$2.46
Q2 FY2025-2.82%
Report Date
May 14, 2025
EPS Beat/Miss
+47.4%
Price Before
$1.42
Price After
$1.38
Q1 FY2025+1.01%
Report Date
Mar 20, 2025
EPS Beat/Miss
+34.3%
Price Before
$1.99
Price After
$2.01
Q4 FY2024-1.09%
Report Date
Nov 13, 2024
EPS Beat/Miss
+46.4%
Price Before
$2.75
Price After
$2.72
Q3 FY2024+6.27%
Report Date
Aug 13, 2024
EPS Beat/Miss
-25.0%
Price Before
$2.55
Price After
$2.71
Avg Beat Reaction+0.09%
Avg Miss Reaction+3.05%
Beat Rate5 / 8 quarters
Largest Move+6.27% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARMP ends December
Armata Pharmaceuticals, Inc. (ARMP) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.39 — missing the analyst consensus of $-0.38 by -2.6%. The next ARMP earnings date is expected around September 1, 2026.
Each quarter, investors track ARMP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARMP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARMP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARMP earnings · 5 questionsArmata Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ARMP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARMP historically reports after market close (AMC).
ARMP earnings datewhen is ARMP earningsARMP next earnings datewhen does ARMP report earningsARMP earnings calendar
▸ Source: FMP · Armata Pharmaceuticals, Inc. SEC filings · US GAAP · Armata Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026